Effect of glutamate receptor antagonists on place aversion induced by naloxone in single-dose morphine-treated rats

機関リポジトリ Web Site

書誌事項

タイトル
Effect of glutamate receptor antagonists on place aversion induced by naloxone in single-dose morphine-treated rats
タイトル別名
  • モルヒネ単回投与ラットにおけるナロキソン誘発場所嫌悪性試験に対するグルタミン酸受容体の関与
著者
河崎, 陽一
学位授与大学
岡山大学
取得学位
博士（医学）
学位授与番号
甲第3338号
学位授与年月日
2007-03-23

この論文をさがす

説明

The neurobiological mechanism underlying the negative motivational component of withdrawal from acute opiate dependence is far from understood. Our objectives were to determine whether the glutamatergic system is involved in the motivational component of morphine withdrawal in acutely dependent rats and such an involvement is associated with dopaminergic neurotransmission. We examined the effects of various kinds of glutamate receptor antagonists on conditioned place aversion (CPA) induced by naloxone-precipitated withdrawal from a single morphine exposure 24 h before. Furthermore, the influence of pretreatment with the dopamine receptor antagonist haloperidol on those effects of glutamate receptor antagonists was also investigated. CPA was attenuated in a dose-dependent manner by all glutamate receptor antagonists examined including the NMDA receptor antagonists (+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclo-hepten-5,10-imine maleate (MK-801) and phencyclidine hydrochloride (PCP), AMPA receptor antagonist 1-(4-aminophenyl)4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine hydrochloride (GYKI 52466), and metabotropic receptor antagonists (+/-)-2-amino-3-phosphonopropionic acid (AP-3) and (+/-)-alpha-methyl-4-carboxyphenylglycine (MCPG). The effects of MK-801, GYKI 52466 and MCPG were blocked by haloperidol.These results suggest that the glutamatergic system involving multiple classes of receptors plays a role in the motivational component of withdrawal from acute morphine dependence, and the function of the glutamatergic system would be closely associated with dopaminergic neurotransmission.

博士論文

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ